-
NEJM Blockbuster of the Year! A comprehensive review of recent developments in the treatment of hepatitis B
Time of Update: 2023-02-03
Based on the current treatment progress, many experts have proposed the concept of "partial functional cure" (that is, the HBsAg level drops to The review points out that there are still a number of innovative therapies in the preclinical research stage, including hepatitis B X gene targeted therapy, cccDNA destabilization therapy, CRISPR-Cas9 gene editing therapy (edit cccDNA), etc.
-
Shanghai Electric 4MW single blade spreader successfully lifted for the first time to break the foreign monopoly
Time of Update: 2022-11-24
Shanghai Electric It is reported that the supply chain of offshore single-blade spreaders has been monopolized by foreign suppliers for a long time, and the purchase price of spreaders has been high.
-
Lecture: 2022 MOE Free Online Campus Training China Pharmaceutical University Station
Time of Update: 2022-08-30
Antibody physicochemical properties analysis 15:00-15:55 Antibody Design Fundamentals - Structure-Based Drug Design 16:00-17:00 Stability prediction and mutation scanning, etc.
Antibody physicochemical properties analysis 15:00-15:55 Antibody Design Fundamentals - Structure-Based Drug Design 16:00-17:00 Stability prediction and mutation scanning, etc.
-
Science heavy: CAR-T technology upgrades without in vitro programming of T cells
Time of Update: 2022-01-22
In the study, published in the internationally renowned journal Science, the researchers delivered modified mRNAs using T cell-targeting lipid nanoparticles (LNPs) as carriers to generate transient CAR-T cells in vivo to attack cardiac fibroblasts .
-
"Nature Communications" publishes the results of Chinese scientists' follow-up research, over 70% of COVID-19 patients remain positive for antibodies within one year
Time of Update: 2021-08-05
In cooperation with Professor Zhang Xinxin from the National Center for Translational Medicine of Shanghai Jiaotong University, Sinopharm’s China Biologics Yang Xiaoming team has taken the lead in revealing the 12-month rise and fall of new crown antibody levels in patients who have recovered from the new crown virus infection in Wuhan, China.
-
The first class 1 new drug
Time of Update: 2021-07-30
On July 24, the CDE official website showed that Qilu Pharmaceutical submitted and accepted a listing application for a new class 1 drug "Yiluok Tablets" .
In October 2019, Qilu initiated a phase III clinical study (CTR20191231) comparing WX-0593 tablets and crizotinib in the treatment of ALK-positive non-small cell lung cancer.
-
Single-Chain Fv Antibodies Expressed in Plants
Time of Update: 2021-03-13
Methods of gene cloning and genetic engineering of immunoglobulins and transgenic plant techniques have given rise to new approaches in plant biotechnology ( 1 ).
Antibodies expressed in plants can also be used to influence and block plant pathogen development and action ( 3 , 4 ).
-
Real-Time Single-Molecule Observation of Green Fluorescent Protein Synthesis by Immobilized Ribosomes
Time of Update: 2021-02-25
We have developed a novel method, using a combination of ribosome display and single-molecule techniques, for monitoring the synthesis, co-translational folding, and maturation of a complete polypeptide chain at the single-molecule level.
-
The Generation and Selection of Single-Domain, V Region Libraries from Nurse Sharks
Time of Update: 2021-01-26
The cartilaginous fish (sharks, skates, and rays) are the oldest phylogenetic group in which a human-type adaptive immune system and immunoglobulins (Igs) have been found.
In addition to their conventional (heavy-light chain heterodimeric) isotypes, IgM and IgW, sharks produce the novel isotype, IgNAR, a heavy chain homodimer that does not associate with light chains.
-
NEJM: Recovery plasma treatment of new crown pneumonia, a wave of three folds to reproduce the dawn
Time of Update: 2021-01-25
The study was supported by a separate study, published in BMJ, detailing: BMJ: Assessment of the therapeutic effectiveness of recovery plasma in patients hospitalized with moderate neocyctic pneumonia This study further looked at the relationship between antibody levels in recovery plasma and the risk of death in patients.
-
Expert Revealed: Epoxy Modifier
Time of Update: 2021-01-10
HeLOXY epoxy modifiers have the same effect on chemical properties as the mechanical properties of thermodynamics, of course, some studies have pointed out that water resistance also depends on hydrocarbon-based content and molecular polarity, and acid-resistant alkalinity is mainly related to the quality of curing agents.
-
Hengrui Pharmaceuticals submitted a new application for fluorine palli's new adaptive disease for ovarian cancer maintenance treatment
Time of Update: 2021-01-01
December 14th, a new drug for the treatment of relapsed ovarian cancer (including fallopian tube cancer and primary peritoneal cancer) with BRCA1/2 mutations was approved by NMPA.
-
Innovative drug for optic neurospinal corditis spectrum disorder (NMOSD)! Chinese and foreign drug IL-6R single anti-Enspryng approved in Taiwan, China
Time of Update: 2020-12-28
data from two randomized controlled Phase III studies (SakuraStar, SAkuraSky) confirmed that enspryng was treated as a monotherapy and baseline in adult patients with AQP4 antibody-positive NMOSD Immunosuppressant (IST, commonly used to manage relapse-related NMOSD symptoms) combined treatment has strong and long-lasting efficacy and good safety: Enspryng significantly reduces the risk of recurrence compared to placebos and lasts up to 96 weeks.
-
Invader Assay for Single-Nucleotide Polymorphism Genotyping and Gene Copy Number Evaluation
Time of Update: 2020-12-13
The Invader� assay (Third Wave Technologies) is a homogeneous, isothermalDNA probe-based method for sensitive detection of nucleic acid sequences.
Detection is achieved through target-specific signal amplification instead of target amplification.
-
Antibody Affinity Maturation by Chain Shuffling
Time of Update: 2020-10-31
To accomplish affinity maturation (increased affinity), the sequence of the antibody is diversified, the mutant gene repertoire is displayed on filamentous phage, and higher-affinity binders are selected on antigen.
Factors such as antibody fragment size, pharmacokinetics, and valency may have a more important impact ( 4 ).
